Monoclonal Antibody Therapeutics Market Research Report by Source, End User, Application, State - United States Forecast to 2027 - Cumulative Impact of COVID-19

Monoclonal Antibody Therapeutics Market Research Report by Source, End User, Application, State - United States Forecast to 2027 - Cumulative Impact of COVID-19

The United States Monoclonal Antibody Therapeutics Market size was estimated at USD 25.60 billion in 2021 and expected to reach USD 30.23 billion in 2022, and is projected to grow at a CAGR 14.39% to reach USD 57.37 billion by 2027.

Market Statistics:

The report provides market sizing and forecast across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

Market Segmentation & Coverage:

This research report categorizes the Monoclonal Antibody Therapeutics to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Source, the market was studied across Chimeric, Human, and Humanized.

Based on End User, the market was studied across Hospitals, Private Clinics, and Research Institute.

Based on Application, the market was studied across Autoimmune Diseases, Cancer, Hematological Diseases, Infectious Diseases, and Ophthalmological Diseases.

Based on State, the market was studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:

We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Monoclonal Antibody Therapeutics market considering the current update on the conflict and its global response.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Monoclonal Antibody Therapeutics Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:

The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the United States Monoclonal Antibody Therapeutics Market, including AbbVie Inc., Amgen Inc., Bayer AG, Biogen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Envigo, F. Hoffmann-La Roche Ltd, GenScript, GlaxoSmithKline Plc, Johnson & Johnson, Merck Sharp & Dohme Corp.,, Novartis International AG, Pfizer Inc, and Sanofi S.A.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the United States Monoclonal Antibody Therapeutics Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the United States Monoclonal Antibody Therapeutics Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the United States Monoclonal Antibody Therapeutics Market?
4. What is the competitive strategic window for opportunities in the United States Monoclonal Antibody Therapeutics Market?
5. What are the technology trends and regulatory frameworks in the United States Monoclonal Antibody Therapeutics Market?
6. What is the market share of the leading vendors in the United States Monoclonal Antibody Therapeutics Market?
7. What modes and strategic moves are considered suitable for entering the United States Monoclonal Antibody Therapeutics Market?

Please Note: PDF & Excel + Online Access - 1 Year


1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.2. Restraints
5.1.3. Opportunities
5.1.4. Challenges
5.2. Cumulative Impact of COVID-19
6. Monoclonal Antibody Therapeutics Market, by Source
6.1. Introduction
6.2. Chimeric
6.3. Human
6.4. Humanized
7. Monoclonal Antibody Therapeutics Market, by End User
7.1. Introduction
7.2. Hospitals
7.3. Private Clinics
7.4. Research Institute
8. Monoclonal Antibody Therapeutics Market, by Application
8.1. Introduction
8.2. Autoimmune Diseases
8.3. Cancer
8.4. Hematological Diseases
8.5. Infectious Diseases
8.6. Ophthalmological Diseases
9. California Monoclonal Antibody Therapeutics Market
9.1. Introduction
10. Florida Monoclonal Antibody Therapeutics Market
10.1. Introduction
11. Illinois Monoclonal Antibody Therapeutics Market
11.1. Introduction
12. New York Monoclonal Antibody Therapeutics Market
12.1. Introduction
13. Ohio Monoclonal Antibody Therapeutics Market
13.1. Introduction
14. Pennsylvania Monoclonal Antibody Therapeutics Market
14.1. Introduction
15. Texas Monoclonal Antibody Therapeutics Market
15.1. Introduction
16. Competitive Landscape
16.1. FPNV Positioning Matrix
16.1.1. Quadrants
16.1.2. Business Strategy
16.1.3. Product Satisfaction
16.2. Market Ranking Analysis, By Key Player
16.3. Market Share Analysis, By Key Player
16.4. Competitive Scenario
16.4.1. Merger & Acquisition
16.4.2. Agreement, Collaboration, & Partnership
16.4.3. New Product Launch & Enhancement
16.4.4. Investment & Funding
16.4.5. Award, Recognition, & Expansion
17. Company Usability Profiles
17.1. AbbVie Inc.
17.1.1. Business Overview
17.1.2. Key Executives
17.1.3. Product & Services
17.2. Amgen Inc.
17.2.1. Business Overview
17.2.2. Key Executives
17.2.3. Product & Services
17.3. Bayer AG
17.3.1. Business Overview
17.3.2. Key Executives
17.3.3. Product & Services
17.4. Biogen Inc.
17.4.1. Business Overview
17.4.2. Key Executives
17.4.3. Product & Services
17.5. Bristol-Myers Squibb Company
17.5.1. Business Overview
17.5.2. Key Executives
17.5.3. Product & Services
17.6. Eli Lilly and Company
17.6.1. Business Overview
17.6.2. Key Executives
17.6.3. Product & Services
17.7. Envigo
17.7.1. Business Overview
17.7.2. Key Executives
17.7.3. Product & Services
17.8. F. Hoffmann-La Roche Ltd
17.8.1. Business Overview
17.8.2. Key Executives
17.8.3. Product & Services
17.9. GenScript
17.9.1. Business Overview
17.9.2. Key Executives
17.9.3. Product & Services
17.10. GlaxoSmithKline Plc
17.10.1. Business Overview
17.10.2. Key Executives
17.10.3. Product & Services
17.11. Johnson & Johnson
17.11.1. Business Overview
17.11.2. Key Executives
17.11.3. Product & Services
17.12. Merck Sharp & Dohme Corp.,
17.12.1. Business Overview
17.12.2. Key Executives
17.12.3. Product & Services
17.13. Novartis International AG
17.13.1. Business Overview
17.13.2. Key Executives
17.13.3. Product & Services
17.14. Pfizer Inc
17.14.1. Business Overview
17.14.2. Key Executives
17.14.3. Product & Services
17.15. Sanofi S.A
17.15.1. Business Overview
17.15.2. Key Executives
17.15.3. Product & Services
18. Appendix
18.1. Discussion Guide
18.2. License & Pricing
List of Figures
FIGURE 1. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET: RESEARCH PROCESS
FIGURE 2. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2021 VS 2027
FIGURE 3. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 4. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY STATE, 2021 VS 2027 (%)
FIGURE 5. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY STATE, 2021 VS 2027 (USD BILLION)
FIGURE 6. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET COMPETITIVE STRATEGIC WINDOW, BY STATE, 2027
FIGURE 7. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET DYNAMICS
FIGURE 8. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2021 VS 2027 (%)
FIGURE 9. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2021 VS 2027 (USD BILLION)
FIGURE 10. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET COMPETITIVE STRATEGIC WINDOW, BY SOURCE, 2027
FIGURE 11. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY CHIMERIC, 2018-2027 (USD BILLION)
FIGURE 12. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HUMAN, 2018-2027 (USD BILLION)
FIGURE 13. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HUMANIZED, 2018-2027 (USD BILLION)
FIGURE 14. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2021 VS 2027 (%)
FIGURE 15. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2021 VS 2027 (USD BILLION)
FIGURE 16. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET COMPETITIVE STRATEGIC WINDOW, BY END USER, 2027
FIGURE 17. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2027 (USD BILLION)
FIGURE 18. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY PRIVATE CLINICS, 2018-2027 (USD BILLION)
FIGURE 19. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTE, 2018-2027 (USD BILLION)
FIGURE 20. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2021 VS 2027 (%)
FIGURE 21. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2021 VS 2027 (USD BILLION)
FIGURE 22. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET COMPETITIVE STRATEGIC WINDOW, BY APPLICATION, 2027
FIGURE 23. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2027 (USD BILLION)
FIGURE 24. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY CANCER, 2018-2027 (USD BILLION)
FIGURE 25. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL DISEASES, 2018-2027 (USD BILLION)
FIGURE 26. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2027 (USD BILLION)
FIGURE 27. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY OPHTHALMOLOGICAL DISEASES, 2018-2027 (USD BILLION)
FIGURE 28. CALIFORNIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 29. FLORIDA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 30. ILLINOIS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 31. NEW YORK MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 32. OHIO MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 33. PENNSYLVANIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 34. TEXAS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 35. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET: FPNV POSITIONING MATRIX, 2021
FIGURE 36. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2021
FIGURE 37. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET COMPETITIVE SCENARIO, BY KEY TYPE, 2021
List of Tables
TABLE 1. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018–2021
TABLE 3. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 4. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY STATE, 2018-2027 (USD BILLION)
TABLE 5. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2027 (USD BILLION)
TABLE 6. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY CHIMERIC, 2018-2027 (USD BILLION)
TABLE 7. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY CHIMERIC, BY STATE, 2018-2027 (USD BILLION)
TABLE 8. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HUMAN, 2018-2027 (USD BILLION)
TABLE 9. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HUMAN, BY STATE, 2018-2027 (USD BILLION)
TABLE 10. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HUMANIZED, 2018-2027 (USD BILLION)
TABLE 11. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HUMANIZED, BY STATE, 2018-2027 (USD BILLION)
TABLE 12. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2027 (USD BILLION)
TABLE 13. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2027 (USD BILLION)
TABLE 14. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY STATE, 2018-2027 (USD BILLION)
TABLE 15. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY PRIVATE CLINICS, 2018-2027 (USD BILLION)
TABLE 16. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY PRIVATE CLINICS, BY STATE, 2018-2027 (USD BILLION)
TABLE 17. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTE, 2018-2027 (USD BILLION)
TABLE 18. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTE, BY STATE, 2018-2027 (USD BILLION)
TABLE 19. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2027 (USD BILLION)
TABLE 20. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2027 (USD BILLION)
TABLE 21. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY STATE, 2018-2027 (USD BILLION)
TABLE 22. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY CANCER, 2018-2027 (USD BILLION)
TABLE 23. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY CANCER, BY STATE, 2018-2027 (USD BILLION)
TABLE 24. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL DISEASES, 2018-2027 (USD BILLION)
TABLE 25. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL DISEASES, BY STATE, 2018-2027 (USD BILLION)
TABLE 26. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2027 (USD BILLION)
TABLE 27. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY STATE, 2018-2027 (USD BILLION)
TABLE 28. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY OPHTHALMOLOGICAL DISEASES, 2018-2027 (USD BILLION)
TABLE 29. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY OPHTHALMOLOGICAL DISEASES, BY STATE, 2018-2027 (USD BILLION)
TABLE 30. CALIFORNIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 31. CALIFORNIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2027 (USD BILLION)
TABLE 32. CALIFORNIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2027 (USD BILLION)
TABLE 33. CALIFORNIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2027 (USD BILLION)
TABLE 34. FLORIDA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 35. FLORIDA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2027 (USD BILLION)
TABLE 36. FLORIDA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2027 (USD BILLION)
TABLE 37. FLORIDA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2027 (USD BILLION)
TABLE 38. ILLINOIS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 39. ILLINOIS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2027 (USD BILLION)
TABLE 40. ILLINOIS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2027 (USD BILLION)
TABLE 41. ILLINOIS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2027 (USD BILLION)
TABLE 42. NEW YORK MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 43. NEW YORK MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2027 (USD BILLION)
TABLE 44. NEW YORK MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2027 (USD BILLION)
TABLE 45. NEW YORK MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2027 (USD BILLION)
TABLE 46. OHIO MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 47. OHIO MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2027 (USD BILLION)
TABLE 48. OHIO MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2027 (USD BILLION)
TABLE 49. OHIO MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2027 (USD BILLION)
TABLE 50. PENNSYLVANIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 51. PENNSYLVANIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2027 (USD BILLION)
TABLE 52. PENNSYLVANIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2027 (USD BILLION)
TABLE 53. PENNSYLVANIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2027 (USD BILLION)
TABLE 54. TEXAS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 55. TEXAS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2027 (USD BILLION)
TABLE 56. TEXAS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2027 (USD BILLION)
TABLE 57. TEXAS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2027 (USD BILLION)
TABLE 58. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET: FPNV POSITIONING MATRIX - SCORES, 2021
TABLE 59. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET: FPNV POSITIONING MATRIX - BUSINESS STRATEGY, 2021
TABLE 60. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET: FPNV POSITIONING MATRIX - PRODUCT SATISFACTION, 2021
TABLE 61. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET RANKING, BY KEY PLAYER, 2021
TABLE 62. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2021
TABLE 63. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET MERGER & ACQUISITION
TABLE 64. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 65. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 66. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET INVESTMENT & FUNDING
TABLE 67. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET AWARD, RECOGNITION, & EXPANSION
TABLE 68. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET: LICENSE & PRICING

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings